Advanced Biotherapy Concepts Engages Cappello Capital Corp. as Its Investment Banking Firm.

Business Editors

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Feb. 28, 2000

Advanced Biotherapy Concepts Inc. (OTCBB:ADVB) today announced, in preparation for expanding its drug development effort, that it has engaged Cappello Capital Corp. of Santa Monica, Calif., to serve as the company's investment banking firm and strategic advisor.

Edmond Buccellato, chief executive officer of Advanced Biotherapy, said, "We are delighted to have an experienced firm represent us as our investment bankers and look forward to working with them as we continue to build on the company's patented and proprietary technology." He added, "We believe the excellent reputation and expertise of Cappello Capital Corp. in the biotechnology and medical industries will be a tremendous asset to the company."

Gerard Cappello, president and CEO of Cappello Capital Corp., stated: "Advanced Biotherapy has developed and patented an exciting technology which could result in important new drugs for a variety of unmet medical needs, and is developing many valuable relationships in the field of autoimmune therapeutics. Based upon our due diligence, we are looking forward to working with the company to develop and implement its business plan."

Cappello Capital Corp. is an investment bank specializing in direct investments of equity securities, both common and preferred stock placements, strategic advisory services and merger and acquisition advisory services. According to Thompson Financial Securities Data, the firm was ranked as the fifth-highest volume underwriter in the world of convertible preferred stock issues for publicly traded companies from 1995 through 1998. The firm's clients include both publicly traded and closely held companies.

Advanced Biotherapy Concepts is a development-stage biotechnology company developing treatments for severe autoimmune diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, insulin-dependent diabetes and AIDS. The company's technology has already shown promise in published clinical studies.

The company's patented and proprietary treatment, which has now been evaluated in approximately 150 patients, neutralizes certain cytokines now confirmed to play a major role in causing these diseases.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the company's public filing with the Securities and Exchange Commission for information about risks that may affect the company.